FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome

View source ↗

Summary

FDA approved Avlayah (tividenofusp alfa-eknm) to treat neurologic manifestations in individuals with Hunter syndrome (MPS II).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hunter Syndrome
• Mucopolysaccharidosis Type Ii

Drugs mentioned

• AVLAYAH (tividenofusp alfa-eknm)

Snippet

The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).